Since there is no consensus sequence directing the initial GalNAc incorporation into mucin peptides, Oglycosylation sites are not reliably predictable. We have developed a mass spectrometric sequencing strategy that allows the identification of in vivo O-glycosylation sites on mucin-derived glycopeptides. Lactation-associated MUC1 was isolated from human milk and partially deglycosylated by trifluoromethanesulfonic acid to the level of core GalNAc residues. The product was fragmented by the Arg-C-specific endopeptidase clostripain to yield tandem repeat icosapeptides starting with the PAP motif. PAP20 glycopeptides were subjected to sequencing by post-source decay matrix-assisted laser desorption ionization mass spectrometry or by solid phase Edman degradation to localize the glycosylation sites. The masses of C-or N-terminal fragments registered for the mono-to pentasubstituted PAP20 indicated that GalNAc was linked to the peptide at Ser 5 ,Thr 6 (GSTA) and Thr 14 (VTSA) but contrary to previous in vitro glycosylation studies also at Thr 19 and Ser 15 located within the PDTR or VTSA motifs, respectively. Quantitative data from solid phase Edman sequencing revealed no preferential glycosylation of the threonines. These discrepancies between in vivo and in vitro glycosylation patterns may be explained by assuming that O-glycosylation of adjacent peptide positions is a dynamically regulated process that depends on changes of the substrate qualities induced by glycosylation at vicinal sites.
Post-translational modification of proteins by glycosylation has extensively been studied in the case of N-linked glycans, and accordingly, rules for the substitution of asparagine residues by dolichol phosphate-linked glycans are well established (1) . While N-glycosylation is directed by the consensus peptide motif Asn-X-(Ser/Thr), no strict sequence dependence is known for the initiation of O-glycosylation. Currently, there are several approaches to the identification of O-glycosylation sites: studies on in vitro O-glycosylation of synthetic peptides (2) (3) (4) or studies on in vivo processed mucin-type glycoproteins (5-7).
The relative merits of both approaches have been discussed (8) . The results obtained so far agree with the statement that there are no clear-cut motifs for the addition of GalNAc at Ser or Thr residues; however, the non-random patterns of O-glycosylation suggest influences of flanking sequences (2). Wang et al. (3) proposed different motifs for threonine and serine glycosylation, and the studies of O'Connell et al. (2) revealed critical positions in the vicinity of putative O-glycosylation sites. The obviously less specific GalNAc addition to Ser/Thr residues compared with N-glycosylation is reflected also in the existence of at least four distinct species of UDP-GalNAc/peptide Nacetylgalactosaminyltransferase(s) (GalNAc-transferase) for which different substrate specificities have been established (9) . Accordingly, the differentiation and organ localization of a cell should determine its characteristic equipment of active GalNAc-transferases (T1-T4) and, hence, the site-specific Oglycosylation of proteins processed within this cell.
Site specificity of O-glycosylation strongly affects the antigenicity of a protein as has been revealed for the highly immunogenic peptide motif PDTR within MUC1 tandem repeats (10) . Most antibodies reactive to the PDTR sequence are more or less influenced by GalNAc incorporation into threonine residues of the flanking motifs VTSA and GSTA by showing a significant enhancement or decrease of their binding activities (10, 11) . In vitro studies have established that preferentially Thr residues within VTSA and GSTA are glycosylated (12) (13) (14) (15) , whereas only Ser within GSTA serves as a substrate to a minor degree (14, 15) .
To establish the actual sites of O-glycosylation on the in vivo processed mucin, we have applied a mass spectrometric sequencing strategy (15) using the MUC1 glycoform in human milk as a model. A fragmentation of the highly glycosylated mucin by specific endopeptidases becomes possible only after a limited deglycosylation with trifluoromethanesulfonic acid (TFMSA). 1 This treatment is reported to result in the removal of complex carbohydrates, but to leave during short reaction times a considerable portion of the core GalNAc residues intact (16, 17) . This partially deglycosylated mucin (GalNAc-MUC1) can be effectively fragmented by clostripain cleaving at Arg-C (18) . Clostripain fragmentation of the tandem repeat peptide results in a series of differentially glycosylated icosapeptides PAP20 as shown in Sequence 1:
As demonstrated previously for a series of in vitro glycosylated peptides corresponding to the MUC1 tandem repeats (TAP25) (15) , the sequencing of PAP20 peptides was possible by mass spectrometric analysis of post-source decay fragments in a MALDI-TOF instrument. Independent evidence for the localization of O-glycosylation sites and, moreover, quantitative estimations of the degree of glycosylation at each site were obtained from solid phase Edman sequencing. The results obtained suggest that in vitro data should be carefully reevaluated by the analysis of in vivo processed glycoprotein and that a prediction of O-glycosylation sites cannot be based solely on peptide sequence.
MATERIALS AND METHODS
Isolation of Mucin-Human milk was obtained from healthy women during days 2-5 of lactation and immediately frozen at Ϫ20°C. Milk samples from multiple donors were thawed at 4°C and combined, and milk fat was separated from skim milk by centrifugation at 3,000 ϫ g (4°C) for 1 h (Fig. 1) . Secretory MUC1 from skim milk was isolated by extraction with hot phenol and subsequent gel filtration on Sephacryl S300 as described previously (19) (Fig. 1 ). This preparation is designated MUC1(skim milk). Milk fat was used for the preparation of human milk fat globule membranes (HMFGM) according to the procedure of Shimidzu and Yamauchi (20) . For the isolation of membraneassociated MUC1, the HMFGM were homogenized and sonicated in 0.45 mM sodium phosphate, 125 mM sodium chloride, pH 7.2 (PBS), containing 4 M urea, before they were extracted with an equal volume of 90% phenol for 30 min at 65°C. The extract was allowed to cool to room temperature; 0.5 volumes of chloroform were added, and the phases were separated by centrifugation at 30,000 ϫ g (10°C) for 30 min. The aqueous phase was dialyzed against several changes of demineralized water, concentrated by ultrafiltration, and applied to a column (2.5 ϫ 100 cm) of Sephacryl S300 equilibrated in PBS. Fractions were analyzed by colorimetric microassays for hexoses (21) and sialic acid (22) and in an enzyme-linked immunosorbent assay with monoclonal antibody BW835. The combined void fractions, containing the mucin, were extensively dialyzed against demineralized water, concentrated by ultrafiltration, and freeze-dried. This preparation is designated MUC1(HMFGM).
SDS-Polyacrylamide Gel Electrophoresis and Immunoblot
Analysis-SDS-polyacrylamide gel electrophoretic separations of mucin samples were carried out in the Mini Protean II gel electrophoresis apparatus (Bio-Rad, Mü nchen, Germany) according to the method of Laemmli. Gradient gels (3-15%), overlaid with a 3% stacking gel, were run at 200-V constant voltage for 50 min and stained with Coomassie Brilliant Blue R-250. In addition, gels were blotted onto polyvinylidene difluoride membranes using a semi-dry blotting apparatus and the buffer system of Towbin et al. (23) . Remaining protein binding sites were blocked with 3% BSA in PBS (1 h, room temperature), and mucin was detected by an overnight incubation with mAb BW835 (Behringwerke, Marburg, Germany, 2 g/ml in 0.5% BSA in PBS) followed by 1-h incubations with biotinylated goat anti-mouse immunoglobulin serum (E 413, Dako, 1:5,000 in 0.5% BSA in PBS) and avidin-conjugated alkaline phosphatase (Boehringer Mannheim, 1:2,500 in 0.5% BSA in PBS) using nitro blue tetrazolium/5-bromo-4-chloro-3-indoyl phosphate as substrate. Alternatively, blotted glycoproteins were detected after oxidation with sodium periodate according to the method of O'Shannessy et al. (24) .
Partial Deglycosylation of Mucin with TFMSA-MUC1(skim milk) or MUC1(HMFGM) were deglycosylated by treatment with anhydrous TFMSA (Sigma, Unterhaching, Germany) in the absence (16) or presence of anisole (17) (Fig. 2) . Lyophilized mucin was resuspended in 0.1 M hydrochloric acid at 4 mg/ml and heated at 70°C for 60 min to hydrolyze sialic acids. Hydrochloric acid was removed by dialysis against demineralized water. Following the method of Sojar and Bahl aliquots corresponding to 0.1-8 mg of native mucin were lyophilized in Teflon-lined screw-cap vials, flushed with argon, and precooled on ice, before 0.2-0.4 ml of TFMSA (Ϫ20°C) were added for each milligram of mucin. The tubes were flushed with argon once more and then immediately closed and incubated on ice for the appropriate time. The reaction was stopped by cooling the tubes on dry ice in methanol and slowly adding 3 volumes of ice-cold 60% pyridine/water. Finally, the deglycosylated samples were dialyzed against several changes of buffer, appropriate for the following manipulations, and stored frozen at Ϫ20°C. The method of Gerken et al. (17) was followed as described.
The time course of N-acetylgalactosamine (GalNAc) exposure during removal of complex glycans by TFMSA treatment was followed by kinetic analysis (Fig. 2) . 0.1 mg of MUC1(HMFGM) was desialylated and treated with TFMSA for 0, 15, 30, and 60 min in the absence of anisole or for 0, 1, 2, and 6 h in the presence of anisole. After neutralization the samples were diluted with 50 mM NH 4 HCO 3 , pH 8.0, and chromatographed on Superdex 75pg (1 ϫ 20 cm) using the same buffer as eluant and a flow rate of 0.4 ml/min. The samples were analyzed by quantitative monosaccharide composition analysis (see below) or by Helix pomatia agglutinin binding to follow the time course of the sugar removal and the immunochemical accessibility of exposed GalNAc. Samples were diluted 1:16 in 0.1 M sodium carbonate, pH 9.6, and 50 l of a serial 1:2 dilution in the same buffer were bound to 96-well polystyrene plates by drying in a desiccator. Remaining protein binding sites were blocked with 3% BSA in PBS at 37°C for 1 h, and the plate was incubated with 50 l of a 2 g/ml solution of biotinylated H. pomatia agglutinin (Sigma) in 0.5% BSA in PBS at 37°C for 1 h. Bound lectin was detected with avidin-alkaline phosphatase (Boehringer Mannheim, Germany, 1:2,500 in 0.5% BSA in PBS) using p-nitrophenyl phosphate as substrate.
Chemical Analysis of Glycans-Amino sugars in the deglycosylated samples were analyzed as peracetylated alditols using gas chromatography/electron impact mass spectrometry (Fison MD800) in the scan mode. 100 l (20%) of the dialyzed samples and 2 g of meso-erythritol were lyophilized in micro-reaction vials and hydrolyzed with 4 N hydrochloric acid for 18 h at 100°C. Subsequent reduction and peracetylation of monosaccharides was performed as described elsewhere (25) . To . Decrease of monosaccharide contents (GalNAc, GlcNAc, and Gal) with reaction time was followed by gas chromatographic composition analysis of MUC1 aliquots.
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analyze total monosaccharides in the deglycosylated and gel-filtrated samples per-O-trimethylsilyl,1-O-methyl esters were prepared according to the method of Chaplin and Kennedy (26) . Gas chromatography of peracetylated alditols was performed on a DB5ms capillary (J & W Scientific, 0.25 mm ϫ 15 m). Splitless sample injection (200°C) was used. The capillary temperature was held constant at 50°C for 1 min, raised to 120°C with 30°C/min, and then to 260°C with 7.5°C/min. The same capillary was used for the analysis of per-O-trimethylsilyl,1-O-methyl esters. The temperature was kept at 100°C for 1 min and then raised to 280°C with 7.5°C/min. On-line mass spectrometry was performed with electron impact ionization at 70 eV in the positive mode. Mass spectra were recorded in the range from 50 to 500 mass units.
A synthetic glycopeptide GPT-(GlcNAc␤1-6GalNAc␣)-TTPITT (kindly provided by Prof. H. Paulsen, Institute of Organic Chemistry, University of Hamburg) or partially deglycosylated MUC1 were treated with 50 mM NaOH, 1 M NaBH 4 for 16 h at 50°C, and after destruction of the excess borohydride with dilute acetic acid the reductively ␤-eliminated alditols were desalted on Dowex 50WX8, followed by removal of borate as its methyl ester, extensive drying and permethylation as described (19) . Gas-chromatography/mass spectrometry of methylated dihexosamine alditols was performed on an MD800 (Fisons). The samples were solubilized in chloroform and injected onto a DB5 capillary column (15 m), which was heated from 100 to 300°C at 10°C/min followed by isothermic elution at 300°C for 10 min. Mass spectra were recorded in cyclic scans from m/z 100 to 800.
Preparation of Partially Deglycosylated MUC1 Glycopeptides-Three aliquots corresponding to 8 mg of native mucin were desialylated and treated with TFMSA according to Sojar and Bahl (16) for 20 min (P1), 30 min (P3), or 60 min (P2) (Fig. 1) . The neutralized samples were dialyzed into 25 mM sodium phosphate, pH 7.5; 0.2 mM calcium acetate and concentrated by ultrafiltration. 0.5 ml (50%) of the concentrated samples (8 mg/ml) were supplemented with 2.5 mM dithiothreitol, and proteolytic digestion was performed by adding 120 g of clostripain (1 mg/ml in 2.5 mM dithiothreitol, 2 mM calcium acetate, activated at room temperature for 3 h) and incubating at 37°C for 24 h. An aliquot of the digest was chromatographed on Superdex 75pg (1 ϫ 20 cm) in 50 mM sodium phosphate, 500 mM NaCl, pH 7.0. Elution of mucin/glycopeptides was registered at 214 nm, and aliquots of the fractionated eluate were measured for MUC1 peptide epitopes (see below). The column had been calibrated with a mixture of synthetic MUC1 tandem repeat oligomers (kindly provided by Dr. J. Hilgers, Free University Hospital, Amsterdam).
Isolation of Partially Deglycosylated MUC1 Glycopeptides by RP-HPLC-Digested partially deglycosylated mucin samples were cleared by centrifugation for 5 min at 15,000 ϫ g and separated by reversed phase-HPLC on a 250 ϫ 4.6 mm PLRP-S column (Polymer Laboratories) ( Fig. 1 and Fig. 3 ). The samples were injected as 5 ϫ 100-l aliquots, and the column was eluted at a flow rate of 1 ml/min using a linear gradient from 2% (v/v) acetonitrile (ACN) in 0.1%(v/v) trifluoroacetic acid (solvent A) to 80% (v/v) ACN in 0.09% (v/v) (solvent B) during 80 min. Peaks were detected at 214 nm, and 1-ml fractions were collected. 10 l of each fraction were used for immunochemical detection with a mixture of the MUC1-specific mAbs BC3 and VA1 (see "Immunochemical Procedures"). Immunoreactive fractions (19 -25 and 26 -30 min) were combined, lyophilized in a speed vac, and rechromatographed on a 250 ϫ 2.1 mm C18 column (Vydac) using a flow rate of 0.25 ml/min and a gradient of 0 -100% solvent B during 100 min (P1, P2). Rechromatography of P3 glycopeptides was performed with a flow rate of 0.3 ml/min and a gradient from 0 to 100% during 80 min. 0.3-ml fractions were collected, and 5 l were used for immunochemical detection as described above. Immunoreactive fractions were lyophilized in a speed vac and used for matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS) or Edman sequencing (Fig. 1) .
Immunochemical Procedures-The monoclonal antibodies BC3 and VA1 are directed against peptide epitopes within the MUC1 tandem repeat sequence and were kindly provided by Dr. Ian McKenzie (Austin Research Institute, Heidelberg, Australia). BW835 (Behringwerke, Marburg, Germany) is specific for exposed core 1 disaccharide within a peptide motif of the MUC1 tandem repeat sequence (27) .
Samples were immobilized onto 96-well polystyrene plates (Nunc, Wiesbaden, Germany), and bound antibodies were quantified by alternating incubations with polyclonal anti-mouse immunoglobulin (Z 259, Dako, Hamburg, Germany) and a complex of alkaline phosphatase/antialkaline phosphatase, as described previously (27) .
Matrix-assisted Laser-desorption Mass Spectrometry (MALDI-MS)-
The matrix CCA (␣-cyano-4-hydroxycinnamic acid; saturated solution in 2/3 aqueous 0.1% trifluoroacetic acid, 1/3 acetonitrile) was mixed 1:1 (v/v) with the probe in 50% methanol, placed (0.7-0.8 l) onto a polished stainless steel target, and air-dried. Linear, reflectron, and PSD mass spectrometric analyses were performed with a MALDI-TOF instrument (Bruker-Reflex, Bruker-Franzen Analytic, Bremen, Germany) (15) using a pulsed UV laser beam (nitrogen laser, ϭ 337 nm).
Amino sugars were measured as peracetylated alditols after hydrolysis in 4 N HCl (23), galactose as trimethylsilyl derivative of its 1-Omethylglycoside after methanolysis (26) . According to the quantitative monosaccharide analyses, the untreated MUC1(HMFGM) contained Gal, GlcNAc, and GalNAc in the molar proportions of 3.5:3.2:1.0. C, gel exclusion chromatography of proteolytically digested GalNAc-MUC1 on Superdex 75pg. The column (1 ϫ 20 cm) which had been calibrated with a series of MUC1 icosapeptide oligomers (25-, 60-, and 100-mer) was run with 50 mM sodium phosphate, 500 mM NaCl, pH 7.0, at a flow rate of 0.4 ml/min. The eluate was registered spectrophotometrically at 214 nm. The inset shows the corresponding immunoreactivity profiles of the eluted fractions using MUC1 tandem repeat peptide-specific antibodies BC3 and VA1. The immunoreactivity of MUC1-derived glycopeptides eluting at 22 min is expectedly lower by orders of magnitude compared with the polyvalent mucin in the void volume. Profile without addition of clostripain (O) or after digestion with the enzyme (---).
FIG. 3. RP-HPLC of a clostripain digest of partially deglycosylated MUC1(HMFGM) (P3) on PLRP-S column.
The chromatographic conditions were as follows: 1 ml/min (flow rate), 2% (v/v) ACN in 0.1% (v/v) trifluoroacetic acid to 80% (v/v) ACN in 0.09% (v/v) trifluoroacetic acid during 80 min (solvent gradient). A, profile of clostripain digest recorded at 214 nm; B, immunochemical profile of MUC1 glycopeptides registered with a mixture of mAb BC3 and VA1; C, re-chromatography of immunoreactive MUC1 glycopeptides on narrow bore Vydac C18 column using the same solvent gradient as above at a flow rate of 0.3 ml/min. Irradiance was slightly above the threshold of ion detection. Residual gas pressure was at 0.8 ϫ 10 Ϫ7 ϫ 10 Ϫ7 mbar. Ion spectra were obtained in the positive ion mode. Acceleration and reflector voltages were set to 28.5 and 30 kV, respectively. The molecular parent ion was isolated with a pulsed field by deflection of all other ions (precursor selection). Complete PSD fragment ion spectra were obtained by stepwise reducing the reflector voltage to produce overlapping mass ranges, combination of the part spectra, and calibration according to the manufacturer's recommendations. No smoothing or filtering was applied to the shown spectra.
Edman Degradation-Glycopeptides were sequenced on a HPJ000G with 3.1 chemistry and a biphasic sequencing column or after covalent attachment to Sequelon AA TM membranes on a Beckman GlycoSite sequenator according to previously published procedures (6, 28) . Quantitation of the serine/threonine HexNAc substitution was calculated using a glycopeptide derived from the Dictyostelium discoideum recombinant expressed glycoprotein PsA, which contains a 100% substituted GlcNAc␤-Thr in position 4. The corrected yield for this cycle (repetitive yield for the glycopeptide ITATPAPT) was 95%. The migration behavior of GlcNAc␤-Thr is almost identical to the corresponding GalNAc␣ derivative on reversed phase-HPLC (see also Refs. 6 and 28).
RESULTS

Isolation of Mucin
A detailed description of the purification procedure and the chemical characterization of MUC1 from human skim milk is given in Refs. 19 and 29. The yield of MUC1(skim milk) we obtained in the present study was 50 mg/1 liter of defatted milk. For MUC1(HMFGM) the total yield was 7 mg calculated for 100 g of wet milk fat. Quality and homogeneity of both preparations were checked by SDS-polyacrylamide gel electrophoresis with 10 g of mucin/lane and subsequent electroblotting, followed by the glycoprotein staining procedure of O'Shannessy or immunochemical detection with the MUC1-specific mAb BW835. For both mucin preparations the glycoprotein stain revealed a single, broad band that hardly entered the 3-15% gel and that was isographic with the single band obtained by staining Western blots with mAb BW835. These data confirm that MUC1 is the major component in both mucin preparations and demonstrate the absence of detectable amounts of contaminating glycoproteins. In addition, there were no visible bands after staining the gels (100 g mucin/ lane) with Coomassie R-250, indicating that MUC1(skim milk) as well as MUC1(HMFGM) were almost free of non-glycosylated protein.
Kinetics of MUC1 Deglycosylation with TFMSA
Although treatment with anhydrous TFMSA is generally regarded as an efficient method for the deglycosylation of proteins (16, 17) , it leaves a significant amount of the peptidelinked GalNAc uncleaved, when used for limited incubation times at 0°C (16, 17) . We took advantage of this fact by using residual core GalNAc as a marker for O-glycosylation sites. Kinetic studies were performed to find conditions where removal of peripheral saccharides was quantitative and the loss of peptide-linked GalNAc could be neglected. Because the presence of GalNAc in MUC1-linked O-glycans is restricted to peptide-linked positions in core 1 (minor) or core 2 (major) structures (19) , 2 , the amount of GalNAc residues and the ratio of GlcNAc/GalNAc, as measured by quantitative monosaccharide analysis, should give a good estimation of the proceeding deglycosylation reaction. In the absence of anisole the removal of complex glycans and the chain truncation to the level of core GalNAc proceeded within 60 min ( Fig. 2A) . Extension of the incubation times over 60 min resulted in substantial losses of the core GalNAc residues which was also reflected in a decreased H. pomatia agglutinin-binding rate (data not shown). 
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On the contrary, deglycosylation in the presence of anisole resulted in decreased reaction rates, and even after prolonged incubation times up to 6 h the residual GlcNAc was detected at 60% relative to the untreated sample (Fig. 2B) . The length of the polylactosamine-type chains on lactation-associated MUC1 and evidence that indicates a stepwise deglycosylation process from the non-reducing terminus of the glycans (17) could explain this observation. On the basis of these quantitative kinetic data the method of Sojar and Bahl (16) was preferred for the preparation of MUC1-derived glycopeptides. As measured by quantitative hexosamine analysis, the content of GalNAc during TFMSA treatments up to 30 min decreased only to 86%, while the GlcNAc content during the same period dropped below 2% (Fig. 2A) . The low amounts of GlcNAc relative to GalNAc detected after 30 min of deglycosylation indicate that residual dihexosamine GlcNAc␤1-6GalNAc␣ corresponding to In Vivo O-Glycosylation on MUC1 Tandem Repeats 24785 a partial structure of the abundant core 2 glycans on MUC1 from skim milk should be present only in trace amounts. This was confirmed by GC/MS analysis of the permethylated alditols derived by reductive ␤-elimination from the partially deglycosylated mucin. Using a synthetic glycopeptide GPT-(GlcNAc␤1-6GalNAc␣)-TTPITT the dihexosamine alditol could be registered in the scan mode at detection limits of 25 fmol per injection. On the basis of this detection limit no GlcNAc␤1-6GalNAc-ol was found on analysis of MUC1 that had been deglycosylated by TFMSA treatment for 30 min. Also according to quantitative Edman degradation data (see below), the amount of GlcNAc␤1-6GalNAc present should be less than 5% of the more common GalNAc substitution, since the corresponding PTH derivatives of serine or threonine were undetectable.
In conclusion, these data demonstrate that 1) TFMSA cleavage of peripheral sugars is rapid, 2) that 86% of GalNAc are retained for up to 30 min, and 3) that residual glycosylation consists of GalNAc and only trace amounts of GlcNAc.
Preparation of Partially Deglycosylated Glycopeptides
MUC1 is a large and complex molecule, and the preparation of defined fragments is a prerequisite for sequencing experiments. Because there are several sites for specific proteolytic cleavage within the MUC1 tandem repeat sequence, we tried the specific enzymatic fragmentation of native MUC1(skim milk) or MUC1(HMFGM) with a variety of proteolytic enzymes (trypsin, staphyloccocus V8 proteinase, clostripain, papaya proteinase IV, Asp-N). The results obtained with these enzymes were unsatisfactory (data not shown), and it turned out that the fully glycosylated mucin expressed in the lactating mammary gland and its desialylated derivative are almost resistant to commercially available specific proteinases. Since non-glycosylated as well as mono-, di-, or tri-GalNAc-substituted synthetic MUC1 peptides (TAPPAHGVTSAPDTRPAPGSTAPPA, designated TAP25) were good substrates (Ͼ90% cleavage as determined by RP-HPLC, data not shown) for clostripain and papaya proteinase IV, it is obvious that, at least for these enzymes, proteolytic resistance should be due to extensive glycosylation of the mucin. In addition these data indicate that proteolytic efficiency can be increased by reducing glycosylation to the level of core GalNAc, and hence, preparative amounts (8 mg each) of MUC1 were partially deglycosylated by treatment with TFMSA for 20 min (P1), 60 min (P2) (skim milk preparations), and 30 min (P3, HMFGM preparation), and the deglycosylated samples were digested with the Arg-C-specific proteinase clostripain. Aliquots of the digest that had been run over Superdex 75pg revealed that according to the profiles registered at 214 nm, about 80% of the mucin had been degraded by the enzyme (Fig. 2C) . Only weak immunoreactivity to MUC1 peptide-specific antibodies corresponding to undigested MUC1 was detected in the excluded fraction (Fig. 2C) . Clostripain-catalyzed fragmentation of MUC1 proceeded mainly to the level of 20-mers (corresponding to one repeat) as revealed by column calibration using a series of repeat oligomers (25-, 60-, and 100-mer). The pool of PAP20 glycopeptides was isolated from crude digests by RP-HPLC on a PLRP-S column. The HPLC profile registered at 214 nm for preparation P3 is shown in Fig. 3A , and the corresponding immunochemical profile, registered by enzyme-linked immunosorbent assay with a mixture of MUC1-specific mAbs (BC3, VA1), is given in Fig. 3B of the digestion buffer, coeluted with the PAP 20 glycopeptides in the main peak at 20 min.
The retention times were in good agreement with those measured for a series of synthetic MUC1 peptides. Non-to triglycosylated TAP25 peptides eluted between 20 and 25 min, and non-glycosylated repeat oligomers, containing three to five tandem repeats, eluted between 26 and 30 min (Fig. 3C) . For each preparation (P1-P3) the fractions between 19 -25 min and 26 -30 min (Fig. 3A) were pooled, dried in a speed vac, and rechromatographed on a narrow-bore Vydac C18 column. After rechromatography the latter fraction was demonstrated by linear MALDI MS not to contain any detectable MUC1-derived glycopeptides. PAP20 glycopeptides (fractions 19 -25 min) were only partially resolved on rechromatography and eluted in different solvent gradients as a broad peak at about 28 min (P1, P2) or 21 min (P3), respectively. Subfractions corresponding to this peak and representing glycopeptides in P1-(27-32), P2-(27-32), and P3- (19 -25) were collected and analyzed in the linear mode MALDI mass spectrometry or for sequencing experiments (P3-(19 -25) ). As demonstrated by gel filtration on Superdex 75pg and by linear MALDI mass spectrometry (see below), the subfractions from rechromatography contained mainly the monomeric tandem repeat peptides.
Glycopeptide Analysis by Linear Mode MALDI Mass Spectrometry
Glycopeptides resulting from clostripain-catalyzed fragmentation of partially deglycosylated MUC1 mucin were collected from the HPLC eluates, and the various fractions obtained from preparations 1 to 3 (P1 to P3) were subjected to MALDImass spectrometry in the linear mode. The positively charged pseudomolecular ions MH (MH ϩ 17, MH ϩ 43.5) registered for PAP20 glycopeptides from preparations 1 and 2 are listed in Table I , and the corresponding data obtained for preparation 3 are presented in Fig. 4 . In summary, only HexNAc carrying PAP20 peptides were detectable in the various fractions on the basis of their pseudomolecular ions and the mass increment of the monosaccharide substituents (203.2 units) (Fig. 4 and Table I) Besides unglycosylated PAP20 (MH 1888.0) glycoforms of PAP20 containing mainly 1-5 sugar residues and trace amounts of higher glycosylated species were identified in fraction P1-27 (Table I) On the other hand, the corresponding fraction P2-27 derived from more extensively deglycosylated MUC1 contained only PAP20 -0 to PAP20 -4 glycoforms. The more polar, higher glycosylated species (PAP20 -3, PAP20 -4, PAP20 -5, etc.) were expectedly eluted in the early fractions of the registered profiles ( Fig. 3 and Fig. 4) , whereas the late fractions contained primarily unglycosylated PAP20 or the corresponding PAP20 -1 and PAP20 -2 species. Moreover, the fractions eluting at higher acetonitrile concentrations were to a minor degree composed of larger glycopeptides that correspond to dimeric repeats PAP40 (less than 10% of the PAP20 peptides according to the signal intensities in the semi-quantitative MALDI MS). In general, the degree of peptide glycosylation as indicated by the pseudomolecular ions of the polar species contained in fractions P1-27 or P2-27 or in fraction P3-20 was expectedly dependent on the duration of TFMSA treatment that had been employed for the different preparations (P1, P2, P3).
Glycopeptide Sequencing by Post-source Decay MALDI Mass Spectrometry
Analysis of post-source decay fragments for the sequencing of glycopeptides was performed on PAP20 -0 to PAP20 -5 isolated in P3.
PAP20 -0 -PSD-MALDI-MS
analysis of the non-glycosylated PAP20 (Fig. 5A) registered at m/z 1888.0 gave a nearly complete series of intense C-terminal y n and (y n Ϫ18) fragment ions, with a main fragment y 2 (Fig. 5D) . The main fragment results from cleavage of the Asp-Thr bond that had been identified also in the previous study on synthetic MUC1 tandem repeat peptides as a preferred cleavage site. The N-terminal fragment ions of the a or b series (a m , b m ) together with their Ϫ17 companions that result from the loss of NH 3 supported the evidence from C-terminal fragmentation, however, were less complete than the y-fragment series (Fig. 5D ). In conjunction with unidirectional subfragment ion series (internal sequence ions) derived from the various proline fragments the peptide sequence of PAP20 could unequivocally be determined as iden-
TABLE II Fragment masses measured for HexNAc-substituted PAP20 -1 peptides
The relative masses m/z measured for the PSD fragments from the C-terminal end (y n ions and their companions) or N-terminal end of PAP-20 -1 (b m ions and their companions) were listed in accordance to the peptide sequence. Masses given in brackets were of low intensity, whereas for ions, indicated by ϩ, accurate mass assignment was impossible. The masses are accompanied by assignments of the fragment species given in brackets, followed by supporting ions (y n or b m companions, x, or a series ions) which provide additional evidence for the cleavage at distinct sites. tical to the MUC1 tandem repeat sequence. On sequencing of the various PAP20 glycoforms by PSD-MALDI-MS, the same series of fragment ions and their companions were registered. However, fragment ions that are potentially glycosylated generally occur at lower intensities. This can be explained, particularly for peptides with a low degree of glycosylation, by the dispersity of each glycoform resulting from a substitution isomery as revealed by the more complex fragment spectra. PAP20 -1 to PAP20 -3-In the PSD spectrum of PAP20 -1 (Fig. 5B) , the monoglycosylated peptide, the HexNAc substitution could be localized at two to three different positions (Thr 14 and Ser 5 and/or Thr 6 ) based on glycosylated C-or N-terminal fragments (Table II) . In the y fragment series ions at m/z 951.1 (y 7 ), 1106.8 (y 9 ), 1245.0 (y 10 ), 1510.0 (y 13 ), or 1580.2 (y 14 ) in conjunction with x ions and y n Ϫ17 or y n Ϫ18 companions indicate glycosylation at one of the positions Thr 14 , Ser 15 , or Thr 19 . Since no glycosylated fragment ions corresponding to y 2 to y 6 were detectable, the GalNAc substitution can be tentatively assigned to Thr 14 . Also PAP20 -2, the glycoform carrying two GalNAc residues, was demonstrated to be a mixture of several position isomers. Unequivocal evidence for a HexNAc substitution was obtained with reference to the position Thr 19 at m/z 480.9 (y 2 ) representing the ion mass of a monoglycosylated fragment (Table III) . The higher glycosylated PAP20 species, PAP20 -3 to PAP20 -5, turned out to be less heterogeneous with regard to the substitution of single sites. Accordingly, the intensity of the signals indicating glycosylation increased and GalNAc substitution could be more specifically localized. The triglycosylated peptide, PAP20 -3, revealed unequivocal evidence for a monoglycosylation of Thr 19 by C-terminal fragment ions at m/z 480.3 (y 2 ) and 692.0 (y 4 ) ( Table IV) Table V) . The intensity of the glycosylated y 2 relative to the non-glycosylated y 2 supports the assumption that an increasing portion of the PAP20 -4 fraction was glycosylated at that position, when compared with peptides in PAP20 -1 to PAP20 -3 (see also Fig. 5C ). The most highly glycosylated C-terminal fragments y 7 (m/z 1562.0), y 9 (m/z 1744.5), y 11 Ϫ17 (m/z 1909.4) which are substituted with four HexNAc residues demonstrate that both positions, Ser 15 and Thr 14 , carry at least one sugar residue (Table V) . The same line of evidence holds true for the analysis of Ser 5 and Thr 6 glycosylation. The triglycosylated, N-terminal fragments b 6 (m/z 1121.9) and b 8 (m/z 1290.9) which comprise both positions should, accordingly, reflect their substitution with HexNAc. Thus, fraction PAP20 -4 reveals the first unequivocal evidence that all putative sites within the MUC1 tandem repeat can be targets for O-glycosylation. PAP20 -5-On analysis of post-source decay fragments derived from PAP20 -5, each of the five putative glycosylation sites could be revealed as HexNAc-substituted. In detail, the C-terminal series of fragments at m/z 480.2 (y 2 ), 692.0 (y 3 ), and 764.0 (y 4 ) indicated glycosylation of Thr 19 with a HexNAc residue ( Fig. 5C and Table VI ). Comparing the signal intensities of the main fragment ion at m/z 480.2 (y 2 ) relative to those at m/z 276.9 (y 2 ) an increasing proportion of Thr 19 -glycosylated species is obvious (Fig. 5, A-C) . The fragment masses corresponding to y 6 and x 6 (containing the mass increments of two HexNAc residues), accordingly, prove that Ser 15 is also glycosylated. Unequivocal evidence for a HexNAc substitution of Thr 14 1192.5 (b 7 ) or 1492.8 (b 8 ) which correspond to tri-or tetraglycosylated ion species, respectively (Table VI) . In summary, all five putative sites are glycosylated with HexNAc residues. The detection of dihexosamines by PSD MALDI MS was restricted to the higher glycosylated species, where this structural component should be enriched. The presence of minor amounts of dihexosamines did not affect the mass specrometric sequencing.
Identification of Glycosylation Sites by Edman Degradation
Amino acids that are substituted with a monosaccharide are readily recovered in the Edman sequenator. Edman degradation of MUC1-derived glycopeptides was performed on a representative mixture of the Vydac C18 HPLC fractions 20 -24 (P3) and on the highly glycosylated species (mainly PAP20 -4 and PAP20 -5) contained in HPLC fraction 20 (P3) of the same run. Fig. 6 shows the corrected and repetitive yields (pmol) of the glycosylated or non-glycosylated PTH-amino acids obtained for the whole PAP20 peptide(s). No indications for the presence of minor sequences were found, and there was not any readable sequence after cycle 20.
Confirming the above reported mass spectrometric findings, all serine and threonine positions within PAP20 were demonstrated to be glycosylated. The relative molar quantities of glycosylated or non-glycosylated Ser or Thr derivatives were determined by correcting the observed yield for the phenylthiohydantoin (PTH)-Ser(HexNAc) or Thr(HexNAc) by a factor of 1.28 which we have shown elsewhere is the correction factor for a fully substituted Thr or Ser (28) . Since the unsubstituted Ser and Thr undergo partial dehydration in the sequenator, they are recovered in much lower yields than their glycosylated counterparts. Hence, only the glycosylated Ser and Thr can be quantitated with any accuracy. Evidence for the presence of a Ser or Thr substituted with a dihexosamine was tested using the GlycoSite, a solid phase Edman sequenator (Beckman Instruments Inc.). GlycoSite analysis of the HPLC fraction 20 (P3) did not indicate the dihexosamine was present, at least at the level of 1 pmol (equivalent to Յ5% glycosylation at any one particular site, data not shown). There was no obvious preference of threonine over serine positions regarding the degree of GalNAc substitution. The most highly glycosylated position was Thr 14 showing 79.6 or 93.9% substitution in the representative mixture or in HPLC fraction 20, respectively. Unexpectedly, the degree of glycosylation at Ser 5 was higher than at the vicinal Thr 6 position, a finding that contrasts with the previous in vitro pattern (14) . At least one-third of the Ser 15 and Thr 19 positions was revealed as glycosylated, when analyzing the representative mixture of glycopeptides. On average 2.7 of the 5 putative sites were calculated to carry a GalNAc substitution. The substitution pattern of individual repeats obviously shows fluctuations and may reflect a random mechanism of GalNAc addition to the peptide core or a limited random deglycosylation by TFMSA.
DISCUSSION
The present contribution reports on the localization of Oglycosylation sites on MUC1 tandem repeat peptides that had been processed in vivo by mammary glandular epithelial cells during lactation. By using controlled conditions for the limited deglycosylation of MUC1 leaving core GalNAc residues intact and by enzymatic fragmentation with clostripain to the level of monomeric repeats, a representative mixture of glycopeptides could be obtained that reflects the site-specific glycosylation status of the lactation-associated mucin. We have demonstrated by mass spectrometric sequencing using PSD-MALDI-MS and by solid phase Edman sequencing that all five putative glycosylation sites within the 20 amino acid repeats serve as substrates for GalNAc-transferase(s). Although in previous in vitro glycosylation studies only the threonine residues within the VTSA and GSTA sequences were identified as the main sites of initial O-glycosylation (12) (13) (14) , and the serine within GSTA was found to be glycosylated to a lower degree (14) , we here present evidence that also threonine within the PDTR motif and serine within VTSA are glycosylated in vivo by glandular epithelial cells of the breast. This discrepancy is not merely explained by taking cell-specific enzyme repertoires into account, since GalNAc-transferase(s) in human milk had been used in previous in vitro studies (14, 15 does not result from short reaction times, since the PDTRP motif was not glycosylated even after incubation periods in the order of days (14, 15) . Furthermore, the observed pattern of in vitro glycosylation has been demonstrated to be independent of the repeat number and, hence, of the substrate peptide length (12) . In conclusion, it has to be assumed that mucin peptide glycosylation under in vivo conditions follows different mechanisms than in vitro and, accordingly, distinct rules. The more selective pattern of O-glycosylation observed in a non-cellular, stochastic system is ruled by flanking peptide sequences or by the corresponding substrate specificities of the various GalNAc-transferases. This holds particularly true if O-glycosylation of synthetic peptides is investigated on the level of monosaccharide incorporation. Previous studies did not address the possibility that glycosylation of Thr or Ser may favorably alter the substrate qualities at vicinal sites that otherwise would not have been used by GalNAc-transferase(s). A dynamic model of initial O-glycosylation includes the possibility that GalNAc addition to poor substrate positions may be mediated by the cooperative action of glycosyltransferases on adjacent sites and the formation of complex glycans that may be necessary for the initiation of glycosylation at these sites due to the carbohydrate-induced conformational changes of the peptide. In support of this hypothesis a recent paper by Brockhausen et al. (30) provided evidence that a negative regulatory influence of vicinal glycosylation is exerted on distinct substrate positions of a peptide. Glycosylation of the PDTRP motif has a significant impact on the immunogenicity and antigenicity of MUC1 (31) . The naked peptide motif is known to be highly immunogenic and plays a crucial role in the non-MHC-restricted cytotoxic T-cell response in cancer patients (32) . Murine monoclonal antibodies reactive to this motif have been demonstrated to bind to MUC1 in a glycosylation-dependent manner (10, 11) . Most of these antibodies are non-reactive to the glycoform of MUC1 expressed by the lactating mammary gland but are strongly binding to the carcinoma-associated glycoform of the mucin. As previously shown, this effect partly results from glycosylation at vicinal sites (10, 14) . However, a direct effect by glycosylation of the PDTR motif cannot be ruled out according to the results of this study. Further investigations on the carcinoma-associated mucin have to be performed to reveal whether the altered antigenicity of MUC1 could be caused by underglycosylation of the PDTR peptide motif.
The reflectron analysis of post-source decay fragments has been established by Kaufmann et al. (33) for the sequencing of peptides and recently applied on the sequencing of glycopeptides by Goletz et al. (15) . The present paper describes for the first time the site-specific glycosylation pattern of a human mucin by using this variant of MALDI-mass spectrometry for the sequencing of proteolytic glycopeptide fragments. This novel approach has previously been tested for a series of synthetic glycopeptides corresponding to the MUC1 tandem repeat (15) . As revealed in this previous study, a sensitive and reliable localization of O-glycosylation sites is feasible by the analysis of post-source decay fragments. The most prominent fragments, the y ion series (34, 35) (Fig. 5D) , represented a nearly complete pattern of ionized scission products from the C-terminal end of PAP20 peptides and comprised a large proportion of the glycosylated fragments. The b series of fragments (34, 35) (Fig. 5D ) from the N-terminal end was less complete and dominated by non-glycosylated species. The preferred cleavage sites within the PAP20 peptide sequence were at the various X-Pro linkages and the Asp-Thr linkage. The major proline fragments by themselves yielded a series of secondary ions corresponding mainly to the y and b series ions. Since the respective primary and secondary fragments were registered as a series of variably glycosylated species, it has to be assumed that each of the glycoforms, PAP20 -1 to PAP20 -5, represented a mixture of positional isomers. The complexity of the PSD mass spectra is further increased by the formation of a m , and to a minor extend of c m , x n , and z n fragments (33, 34) , and their identification may sometimes become difficult by overlapping fragment masses and a restricted mass accuracy. However, within a limited mass range only small deviations from the calculated masses were observed which showed, moreover, the same tendency and similar extents. In support of the reliability of the mass spectrometric sequencing approach, fragment identification was based on a series of accompanying ions like y n Ϫ 17, y n Ϫ 18 originating from the loss of NH 3 or water, respectively, which are sometimes of higher intensity than the y or b series ions. Considering the various diagnostic fragment ion series, the glycosylation status at individual sites could be unequivocally determined on the basis of several overlapping fragments. The amounts of dihexosamines may have been overestimated on the basis of the mass spectrometric data due to the enrichment of this component in the highly glycosylated PAP20 species. GC-MS analysis of permethylated alditols and solid phase Edman degradation have revealed that GlcNAc␤1-6GalNAc should be present only in trace amounts. More complex glycans containing additional hexose were not detectable in the glycopeptide fractions of partially deglycosylated mucin according to the pseudomolecular ions registered in linear MALDI-mass spectrometry. It has to be emphasized that the glycopeptides under study had been derived from MUC1 deglycosylated in the absence of anisole. In the presence of the radical scavenger the efficiency of deglycosylation decreased strongly and even after hours the polylactosamine-type chains were only partially cleaved (approximately 50%). Accordingly, the conditions of deglycosylation with TFMSA have to be optimized for each glycoprotein, since the structure of the glycans and their chain lengths seem to influence the kinetics of the reaction. The results of mass spectrometric sequencing were confirmed by an independent method using a solid phase variant of automated Edman sequencing (8) . This technique has the advantages that the glycosylated amino acid derivatives can be identified and quantified, which gives the opportunity to estimate the degree of glycosylation at each site. In the present study it was possible to estimate the percentage of glycosylation at the five putative sites within a peptide repeat. The quantitative data revealed that there is no preference of threonine substitution over serine in vivo and that the pattern of lactation-associated MUC1 deviates also in this respect from the previously analyzed in vitro pattern (14) . The mass spectrometric strategy, on the other hand, yields more structural information by allowing also the concomitant sequencing of the TABLE VI Fragment masses measured for HexNAc-substituted PAP20 -5 peptides The relative masses m/z measured for the PSD fragments from the C-terminal end (y n ions and their companions) or N-terminal end of PAP20 -5 (b m ions and their companions) were listed in accordance to the peptide sequence. For further details refer to Table II. y n Amino acid sequence sugar moiety (15) . This becomes of particular interest if more complex glycans are involved. Moreover, in cases of unresolved glycoforms (i.e. PAP20 -1 to PAP20 -5), PSD MALDI mass spectrometry offers the possibility to focus on single glycoforms by precursor selection and to reveal individual patterns of glycosylation instead of "statistical" patterns. With reference to the MUC1 glycoform in human milk the mass spectrometric approach has revealed for the first time that this mucin unlike other well characterized glycoproteins exhibits varying patterns of site-specific O-glycosylation within the tandem repeats. All possible glycoforms of the icosapeptide units were found from mono-to penta-substituted PAP20, and moreover, the existence of different positional isomers was indicated by the mass spectrometric fragmentation patterns and by the Edman degradation data.
In conclusion, the results presented underline the need for reinvestigating O-glycosylation of proteins from a different point of view. Although currently a search for O-glycosylation motifs analogous to the well established N-glycosylation signal has dominated a series of in vitro studies, the low selectivity observed on in vivo glycosylated MUC1 tandem repeats suggests alternative mechanisms that regulate the initiation of O-glycosylation at distinct sites. Enzymatic studies on the basis of glycosylated substrate peptides should reveal insight into a dynamic process of site-specific modulation of substrate qualities. This model implies that the peptide sequence alone not necessarily determines the glycosylation at distinct sites. Consequently, even the analysis of in vivo processed peptides may not reveal generally applicable rules for the prediction of Oglycosylation sites. A prediction of O-glycosylation sites on MUC1 tandem repeats using neural networks trained on data material consisting of 48 mammalian glycoproteins (36) was in accordance with our findings by revealing that each of the five putative sites should be glycosylated with a probability of at least 50%.
A similar approach to the identification of O-glycosylation sites on in vivo processed mucin has recently been published for the porcine submaxillary mucin (37) using tryptic fragmentation of the partially deglycosylated protein core and Edman degradation for the sequencing of the glycopeptides.
Further investigations will have to explore whether complex glycosylated mucin fragments obtained by proteolytic cleavage can be analyzed in the same way. Mass spectrometric sequencing of Pronase-stable glycopeptides could yield information on glycan biosynthesis in distinct peptide positions. While the primary structures of the major glycans from human skim milk MUC1 have been characterized (19, 38) , it is not known whether their localization within the tandem repeats might be structure-dependent or stochastic. -GalNAc from the MUC1 peptides PAP20 -1 to PAP20 -6. Both glycoamino acids elute as diastereomers. Representative chromatograms from the sequencer with a set of standards (below) are shown. Using the HPJoooG sequencer results in an overlap of retention times of the glycoamino acids with some of the amino acids, but the distinctive diastereomers present in both Ser and Thr substituted PTH-glycoamino acids makes the assignments obvious. C, the expanded HPLC profile for Thr 19 and Asp 18 showing the diastereomers of PTH-Thr 19 GalNAc over the background in the previous cycle. The unsubstituted PTH-Thr is also resolved and used in the quantitation.
